Parabiosis and young blood

Parabiosis and young blood refers to a line of experiments in which the circulatory systems of a young and an old animal are joined, and to the effort to extract from those experiments a treatment that can be given to people. In mice, heterochronic parabiosis improves tissue repair, neurogenesis and several molecular measures of age in the older partner, one of the more striking results in biogerontology. Translation has been troubled. The best-known candidate factor is disputed, an alternative interpretation attributes the effect to dilution instead of anything youthful, and the human market ran far ahead of the science.

§The experiments

In surgical parabiosis, two animals are joined along a flank incision so that a shared vasculature develops. The technique dates to Paul Bert's rat experiments in 1864 and was used through the twentieth century to study endocrine and metabolic signals. Mid-century work reported that old rats joined to young partners survived longer than unjoined controls, in studies with small numbers and considerable surgical mortality.

The modern field begins in 2005, when Conboy and colleagues showed that exposing an old mouse to a young circulation restored the activation of muscle satellite cells and liver progenitors, largely by recovering Notch signalling.¹ The aged cells themselves were not irreversibly damaged; they were responding to their environment. That reframing tied the result directly to Stem cell exhaustion. It also suggested that circulating signals impose a share of what looks like intrinsic aging, a systemic account of the Hallmarks of aging in place of a cell-autonomous one. The candidate signals include the secreted products of senescent cells and the chronic immune activation of Inflammaging, which is why senescent-cell burden and plasma composition are often studied together.

Later work extended the finding to the brain. Old blood was shown to impair neurogenesis in young mice, implicating specific circulating chemokines, and young plasma alone was reported to improve synaptic plasticity and performance on memory tasks in old mice.² Umbilical cord plasma produced similar effects, with the metalloproteinase inhibitor TIMP2 identified as one mediator.³ A 2023 study reported that a period of heterochronic parabiosis followed by separation left old mice with lower epigenetic-age estimates and a modest increase in remaining lifespan.⁴

§The GDF11 dispute

GDF11, a circulating TGF-β family protein, shows the field's difficulties most clearly. Beginning in 2013, one group reported that GDF11 declines with age and that restoring it reverses cardiac hypertrophy, improves skeletal muscle regeneration and enhances brain vasculature.⁵ The papers appeared in leading journals and drove substantial commercial interest.

In 2015 a rebuttal from an industrial group reported the opposite. It found that the antibodies and assays used could not distinguish GDF11 from the closely related protein myostatin, that GDF11 does not decline with age in the way claimed, and that giving it impairs muscle regeneration instead of improving it.⁶ The exchange has never been fully resolved. It bears directly on Myostatin inhibition, since the two proteins share receptor pathways and much of the reagent problem.

Young factors or old factors?

The intuitive reading of parabiosis is that young blood supplies something restorative. The alternative is that old blood contains inhibitory factors and the young partner simply dilutes them. Replacing about half the plasma of old mice with saline and albumin, with no young blood at all, produced improvements comparable to parabiosis in several tissues.⁷ If dilution is the mechanism, the therapeutic target is removal, not transfusion.

§Confounds

Parabiosis is a crude instrument. Joined animals share far more than plasma: the young partner's kidneys, liver, lungs, spleen and bone marrow filter and service both bodies. An old animal in parabiosis in effect gains a second set of young organs, and improvements in its tissues may reflect better clearance of metabolic waste and not the delivery of any signalling molecule. Immune cells cross between partners, and feeding, activity and thermoregulation change. Results from plasma transfer alone, which removes most of these confounds, are consistently weaker than results from surgical joining, a pattern suggesting that organ sharing contributes substantially.

Nor are the relevant circulating factors necessarily "youth" factors in any general sense. Plasma from exercised mice transfers benefits to sedentary ones, and exercise changes the same broad classes of protein. No one has cleanly separated a rejuvenation signal from an ordinary exercise response.

§Human attempts

Human work has taken three forms, and none has produced convincing evidence of benefit.

Plasma infusion trials. A small study infusing plasma from young donors into patients with Alzheimer's disease established feasibility and tolerability without addressing efficacy. The company behind it moved toward defined plasma fractions instead of whole plasma before it was acquired. A separate line of work using therapeutic plasma exchange with albumin replacement in Alzheimer's reported slowed decline in a subgroup, a result that remains debated.

Commercial young-plasma clinics. A US startup sold transfusions of young donor plasma to paying customers for general anti-aging purposes. In 2019 the FDA issued a public statement warning that infusions of plasma from young donors for aging, memory or other conditions have no proven benefit and carry the known risks of transfusion, including allergic reaction, circulatory overload and infection.⁸ The clinic model has recurred since in less regulated jurisdictions.

Plasma exchange in healthy adults. Small studies of therapeutic plasma exchange in older volunteers have reported changes in inflammatory and proteomic panels and in clock-based age estimates. A sham-controlled trial published in 2025 assigned 42 adults over 50 either to plasma exchange with albumin replacement (in one arm with added intravenous immunoglobulin) or to a sham procedure. Several epigenetic clocks read lower than in the sham group at an intermediate sampling point, but no group differed significantly from sham at the final one, and functional, cognitive and symptomatic outcomes were not assessed.⁹ These are surrogate measures, and a shift in a biological-age estimate is not evidence of functional improvement. The most publicized individual case, that of Bryan Johnson in 2023, was not a two-way swap. Plasma from his 17-year-old son was infused into Johnson, and Johnson's plasma into his 70-year-old father, as one of six monthly one-litre "young plasma exchanges" in his heavily measured Quantified self regimen. In July 2023 Johnson announced that he was stopping them because his biomarkers showed no benefit, a single uncontrolled self-report.¹⁰

§Risks

Plasma is a biological product with an established risk profile: transfusion reactions, transfusion-associated circulatory overload, transfusion-related acute lung injury and residual infectious risk. These risks are accepted in the treatment of bleeding or immune disease, but they are not obviously acceptable for a healthy person pursuing an unproven benefit. Repeated large-volume exchange also removes clotting factors, antibodies and drugs along with whatever the target is, and it requires replacement fluids that carry their own costs. A large market for young plasma would raise donor-supply questions and interact with existing blood-donation systems. That is a distributional problem in its own right, related to those discussed under Access and inequality and to the wider search for manufactured blood products.

§Outlook

What this line of work has produced of lasting use is not transfusion. It has identified specific circulating proteins that change with age and have measurable effects when manipulated, a target list that feeds into systemic gene therapy, recombinant protein programmes and the broader project of measuring systemic aging. Klotho, TIMP2 and exercise-induced factors are being pursued individually, where dose and mechanism can be controlled in a way whole plasma never allows.

Removal is the mirror strategy. If old plasma carries inhibitory factors, the therapeutic act is subtraction: targeted apheresis for specific proteins, or clearance of the cells producing them, which is the logic of Senolytics. Either version would have to be tested against functional endpoints and not against the biomarker panels that dominate current reports.

The open question is whether the parabiosis effect will break down into a small number of tractable molecules or depends on wholesale exchange of a circulatory environment. If the latter, there may be no drug on the other side of these experiments at all, only the demonstration that aged tissue retains more capacity than it displays. That is the same premise behind Epigenetic reprogramming.

§See also

• Stem cell exhaustion
• Epigenetic reprogramming
• Myostatin inhibition
• Senolytics
• Aging biomarkers
• Gene therapy for aging
• Hallmarks of aging
• Inflammaging

§References